Page 980«..1020..979980981982..9901,000..»

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute…

Posted: June 28, 2020 at 5:43 am

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

http://www.citiuspharma.com

The rest is here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

Posted in Cell Therapy | Comments Off on Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute…

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO – Endpoints…

Posted: June 28, 2020 at 5:43 am

A week after updating their S-1 in search of at least $115 million on the hot biotech IPO market, Poseida Therapeutics says its also raised a fresh venture round a little more than a year after its last.

The first time around, after Poseida delayed its IPO during a government shutdown, the biotech reported a $150 million C round. This time around, its adding $110 million more from Fidelity Management Research Company and others.

Theres no word in the biotechs statement on Novartis, which bought up half of the equity for the Series C cash with a $75 million investment.

According to the SEC filing, Novartis which fielded the first, somewhat troubled CAR-T owns 14.9% of the company, with Malin in for 23.2%, though those numbers may have changed now.

The big beneficiary is CEO Eric Ostertag, who controls 12.6 million shares 25.4% through various family trusts.

Poseidas big idea involves the use of a non-viral DNA tech that they say can be used to gather a bigger concentration of stem cell memory T cells that can avoid the exhaustion that limits the efficacy of the pioneers a central theme in cell therapy 2.0.

Ostertag picked up his PhD in molecular biology at Penn and went on to a career that included a variety of biotech startups.

Link:
Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO - Endpoints...

Posted in Cell Therapy | Comments Off on Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO – Endpoints…

COVID-19 Impact on Global CAR T Cell Therapy Market 2020: Industry Trends, Size, Share, SWOT Analysis by Top Key Players and Forecast Report to 2026 -…

Posted: June 28, 2020 at 5:43 am

Theglobal CAR T cell therapy marketwas estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026.

Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1261434

Chimeric Antigen Receptor(CAR) T celltherapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patients cancer cells.

The growing prevalence of cancer across the world, technological advancement & reliable treatment for cancer, growing pharmaceutical industry, and rise in the number of cell therapy clinical studies are driving the growth of the market globally.

However, side-effects of CAR T-cell therapy and high cost of treatment are the major factors expected to hamper the growth of the global market.

Theglobal CAR T cell therapy marketis primarily segmented based on different target antigen, application, and regions. On the basis of target antigen, the market is divided into CD19, CD22, and others. The applications covered in the study include acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and others.

CAR T Cell Therapy Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Novartis AG Kite Pharma Pfizer, Inc. Cellectis Autolus Therapeutics PLC CARsgen Therapeutics

Report Covers Market Segment by Types:

CD19 CD22 Others

Global CAR T Cell Therapy Industry 2019 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2019 @https://www.orianresearch.com/checkout/1261434

Report Covers Market Segment by Applications:

Acute Lymphoblastic Leukemia Diffuse Large B-Cell Lymphoma Other Applications

Key Benefits of the Report:

Global, and regional, product type & application market size and their forecast from 2019-2026 Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing the growth of the market

Detailed analysis on industry outlook with market specific PEST analysis, and Supply Chain to better understand the market and build expansion strategies Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points Analysis on key players strategic initiatives and competitive developments, such as agreements & joint ventures, mergers & acquisitions, expansion, and new product launches in the market Expert interviews and their insights on market trends, market shift, current and future outlook, and factors impacting vendors short term & long term strategies Detailed insights on emerging regions, product type and application with qualitative and quantitative information and facts Identification of the key patents filed in the field of CAR T Cell Therapy equipment and other related technologies.

Target Audience:

CAR T Cell Therapy providers Traders, Importer and Exporter Raw material suppliers and distributors Research and consulting firms Government and research organizations Associations and industry bodies

Inquire more about CAR T Cell Therapy Market report @https://www.orianresearch.com/enquiry-before-buying/1261434

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with theKey Industry Participants (KIPs) which typically include:

Original Equipment Manufacturer Component Supplier Distributors Government Body & Associations Research Institute

Table of Content

1 Executive Summary2 Methodology And Market Scope3 CAR T Cell Therapy Market Industry Outlook4 CAR T Cell Therapy Market By End User5 CAR T Cell Therapy Market Type6 CAR T Cell Therapy Market Regional Outlook7 Competitive LandscapeEnd of the reportDisclaimer

Customization Service of the Report:Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (832) 380-8827 | UK: +44 0161-818-8027Email:[emailprotected]Website: http://www.orianresearch.com

More here:
COVID-19 Impact on Global CAR T Cell Therapy Market 2020: Industry Trends, Size, Share, SWOT Analysis by Top Key Players and Forecast Report to 2026 -...

Posted in Cell Therapy | Comments Off on COVID-19 Impact on Global CAR T Cell Therapy Market 2020: Industry Trends, Size, Share, SWOT Analysis by Top Key Players and Forecast Report to 2026 -…

Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right) – The Conversation US

Posted: June 28, 2020 at 5:43 am

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization, at least 2.2 billion people in the world have some form of visual impairment. In the United States, approximately 200,000 people suffer from inherited forms of retinal disease for which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances because my laboratory is focusing on designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to the first ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease, Leber congenital amaurosis Type 2.

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light blindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involved inserting a healthy copy of the mutated gene directly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels, it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthrough gene editing technology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene called CEP290 to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of the first ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves using shorter yet functional forms of the CEP290 protein that can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developed a revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

[Get our best science, health and technology stories. Sign up for The Conversations science newsletter.]

Continued here:
Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right) - The Conversation US

Posted in Cell Therapy | Comments Off on Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right) – The Conversation US

STEM CELLS | VitaDrip IV Therapy | Texas

Posted: June 26, 2020 at 10:46 pm

Advantages of Umbilical Cord Stem Cells

Anyone can be treated since Mesenchymal Stem Cells (MSCs) are immune system privileged. No blood matchingnecessary.

.

Ethical issues are avoided.

(All umbilical cords are donated by mothers who gave birth tohealthy, live babies)

.

Harvesting process is painless.

(No need to collect stem cells through invasive procedures such as liposuction or bone marrow collection)

.

Differentiation potential is broad.

(Stem cells an be integrated into any cell. IE: heart, skin, nerve, muscle, etc...)

.

Self-renewal with rapid doubling time.

(Approx. 40 hours per cycle)

.

BEST anti-inflammatory activity, immune modulating capacity and ability to stimulateregeneration.

.

Can be administered multiple times in uniform dosages that contain high cell counts.

.

Immunogenicity (allergic reaction) is low.

.

Tumor growth has NOT been detected.

.

Human Umbilical Cord Tissue (HUCT) contains an abundant supply of MSCs.

.

HUCT MSCs proliferate/differentiate moreefficientlythan other types of stem cells and therefore considered to be more potent.

Continued here:
STEM CELLS | VitaDrip IV Therapy | Texas

Posted in Texas Stem Cells | Comments Off on STEM CELLS | VitaDrip IV Therapy | Texas

Testosterone replacement therapy | Valley Health – Mat-Su Valley Frontiersman

Posted: June 25, 2020 at 1:50 pm

Testosterone levels begin to decline in men at about 40 years of age. Testosterone levels drop about 1% per year- unlike the rapid, dramatic decline in estrogen that women experience at menopause. Over time, the decline is significant and can be clinically important. However, at least 75% of older men continue to maintain their levels within the normal range. Among men that would benefit from testosterone therapy, the Institute of Medicine estimates that only 5% are on treatment.

Symptoms of a low testosterone may include changes in sexual function including reduced sexual desire, fewer spontaneous erections and infertility. It is rarely the cause of erectile dysfunction. Even among men with low testosterone that have erectile dysfunction, only a very small number see this improve with testosterone therapy. Other symptoms include, decrease in muscle mass and strength, decrease in bone density, anemia (low numbers of red blood cells) and increase in body fat. Some men may also experience depression, decreased motivation and a decline in their memory.

Testosterone levels vary by time of day. The highest levels are at 8 am. The normal range for testosterone is based on blood tests draw at 8 am. Therefore, if you have your levels drawn to evaluate your need for therapy, make sure they are drawn at 8 am. Low values are defined as levels below 200 ng/dL. If you value is low, a second level is required to confirm the diagnosis and to qualify you to have your insurance company pay for therapy. Testosterone is a controlled substance and its use is tightly regulated by the Food and Drug Administration. You must have clearly abnormal values in order to qualify to receive treatment.

A small number of men experience immediate side effects including: acne, breast enlargement or tenderness and swelling in the ankles. Red blood cell counts may also rise that increase your risk of blood clotting. Finally, testosterone can worsen sleep apnea a condition that causes severe snoring and cause you stop breathing for short-intervals during the night. You should not start testosterone if you have sleep apnea and are not on treatment for it.

Long-term complications may include an increase in healthy prostate tissue cause symptoms of obstruction. It does not cause prostate cancer, but is cancer is present, it will stimulate it to grow. Finally, there are concerns that testosterone may cause an increase in heart attacks, strokes and death from cardiovascular disease. The data on this are mixed and large scale studies are currently underway in an attempt to see if it truly increases the risk of cardiovascular disease and death.

Your therapy is monitored at 6-month intervals with blood tests for testosterone levels, blood counts and cholesterol levels. Prostate specific antigen (a protein that reflects the amount of prostate tissue) is monitored annually looking for an increase in prostate tissue both healthy are cancer. You may require further evaluation if this level rises too far or too fast. With proper monitoring, testosterone therapy can be safe and effective.

Dr. Samuel Abbate is a local physician practicing in Wasilla.

See original here:
Testosterone replacement therapy | Valley Health - Mat-Su Valley Frontiersman

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone replacement therapy | Valley Health – Mat-Su Valley Frontiersman

Impact Analysis of Covid-19 On Testosterone Replacement Therapy Market Driver, Trends, Applications & Business Strategy Forecast 2027 | Endo…

Posted: June 25, 2020 at 1:50 pm

A new business intelligence report released by CMI with title Global Testosterone Replacement Therapy Market Insights, Forecast to 2027 that targets and provides comprehensive market analysis with future prospects to 2024. The analysts of the study have garnered extensive research methodologies and data sources (i.e. Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends.

If you are involved in the Global Testosterone Replacement Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Coherent Market Insights

Request Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2024

This study categorizes the global Testosterone Replacement Therapy breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis. Global Testosterone Replacement Therapy market size will increase to Million US$ by 2027, from Million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2020 to 2027 as the forecast period to estimate the market size for Testosterone Replacement Therapy. This report focuses on the top manufacturers Testosterone Replacement Therapy capacity, production, value, price and market share of Testosterone Replacement Therapy in global market. The following manufacturers are

Competition Analysis:

Some of key competitors or manufacturers included in the study are AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Detailed Segmentation:

By Active Ingredient TypeTestosteroneMethyl TestosteroneTestosterone UndecanoateTestosterone EnanthateTestosterone CypionateBy Route of AdministrationInjectablesParenteral

Market Analysis by Geographies:

This report is segmented into key Regions to identify significant trends and factors driving or inhibiting the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments., To strategically analyze each submarket with respect to individual growth trend and their contribution to the market. & to analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. With Production Development, Sales, and Regional Trade & Forecast.

Stay up-to-date with Global Testosterone Replacement Therapy market research offered by CMI. Check how key trends and emerging drivers are shaping this industry growth as the study avails you with market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, shares, trend and strategies for this market. In the Testosterone Replacement Therapy Market Analysis & Forecast 2020-2027, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2027, growing at a CAGR of XX% between 2020 and 2027. The production is estimated at XX million in 2017 and is forecasted to reach XX million by the end of 2027, growing at a CAGR of XX% between 2020 and 2027.

Get PDF Brochure Report @https://www.coherentmarketinsights.com/insight/request-pdf/2024

Some of the Points cover in Global Testosterone Replacement Therapy Market Research Report is:

Chapter 1: Overview of Global Testosterone Replacement Therapy Market (2020-2027)

Chapter 2: Market Competition by Players/Suppliers 2015 and 2020

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2015-2020)

Chapter 4, 5 and 6: Global Testosterone Replacement Therapy Market by Type, Application & Players/Suppliers Profiles (2015-2020)

Chapter 7, 8 and 9: Global Testosterone Replacement Therapy Manufacturing Cost, Sourcing & Marketing Strategy Analysis

Chapter 10 and 11: Testosterone Replacement Therapy Market Effect Factors Analysis and Market Size (Value and Volume) Forecast (2020-2027)

Chapter 12, 13, 14 and 15: Global Testosterone Replacement Therapy Market Research Findings and Conclusion, appendix and data source

Some of the key questions answered in this report:

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Buy This Complete A Business Report @https://www.coherentmarketinsights.com/insight/buy-now/2024

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahEmail:[emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Read this article:
Impact Analysis of Covid-19 On Testosterone Replacement Therapy Market Driver, Trends, Applications & Business Strategy Forecast 2027 | Endo...

Posted in Testosterone Replacement Therapy | Comments Off on Impact Analysis of Covid-19 On Testosterone Replacement Therapy Market Driver, Trends, Applications & Business Strategy Forecast 2027 | Endo…

Global Testosterone Replacement Therapy Market to reach US$ 1300 mn by 2025 – Jewish Life News

Posted: June 25, 2020 at 1:50 pm

Los Angeles, United State: Complete study of the global Testosterone Replacement Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Testosterone Replacement Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Testosterone Replacement Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Segmental Analysis

The report has classified the global Testosterone Replacement Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Testosterone Replacement Therapy manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Testosterone Replacement Therapy industry.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)

https://www.qyresearch.com/sample-form/form/1637119/global-testosterone-replacement-therapy-market

Global Testosterone Replacement Therapy Market by Product Type: Gels, Injections, Patches, Other

Global Testosterone Replacement Therapy Market Application: Hospitals, Clinics, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Testosterone Replacement Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Testosterone Replacement Therapy market include: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Key questions answered in the report:

Get Full Report in your Inbox within 24 hours At USD(3350):

https://www.qyresearch.com/settlement/pre/756ac6bd7344136bec84d935754049a8,0,1,Global-Testosterone-Replacement-Therapy-Market-Report-History-and-Forecast-Breakdown-Data-by-Manufacturers-Key-Regions-Types-and-Applicatio

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, database and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database, etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Continue reading here:
Global Testosterone Replacement Therapy Market to reach US$ 1300 mn by 2025 - Jewish Life News

Posted in Testosterone Replacement Therapy | Comments Off on Global Testosterone Replacement Therapy Market to reach US$ 1300 mn by 2025 – Jewish Life News

GLOBAL TESTOSTERONE REPLACEMENT THERAPY MARKET 2020 BY LATEST TECHNOLOGIES, APPLICATIONS, KEY COMPANIES, PRODUCTS, REVENUE AND GROWTH OPPORTUNITIES…

Posted: June 25, 2020 at 1:50 pm

In this report, our team research the global Testosterone Replacement Therapy market by type, application, region and manufacturer 2014-2019 and forcast 2020-2025. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers sales, price, revenue, cost and gross profit and their changes. Whats more, we will display the main consumers, raw material manufacturers, distributors, etc.

To access the sample report of the Testosterone Replacement Therapy market visit at:https://www.orbisresearch.com/contacts/request-sample/4257835

Global Testosterone Replacement Therapy market competition by top manufacturers/players, with 1% Biotin sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

GelsInjectionsPatchesOther

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Testosterone Replacement Therapy for each application, including

HospitalsClinicsOthers

Geographically, this report split Global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of 1% Biotin for these regions, from 2012 to 2023 (forecast), including

ChinaUSAEuropeJapanKoreaIndiaSoutheast AsiaSouth America

If you have any special requirements, please let us know and we will offer you the report as you want.

Click to access full pageshttps://www.orbisresearch.com/reports/index/global-testosterone-replacement-therapy-sales-market-sales-revenue-and-competitors-analysis-of-major-market-from-2014-2026

Table of Contents:

1 Report Overview2 Market Analysis by Types3 Product Application Market4 Manufacturers Profiles/Analysis5 Market Performance for Manufacturers6 Regions Market Performance for Manufacturers7 Global Testosterone Replacement Therapy Market Performance (Sales Point)8 Development Trend for Regions (Sales Point)9 Upstream Source, Technology and Cost10 Channel Analysis11 Consumer Analysis12 Market Forecast 2020-202513 Conclusion

For More Information, Enquiry and Avail Discounts at-https://www.orbisresearch.com/contacts/enquiry-before-buying/4257835

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager, Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas, 75204, U.S.A.

Phone No.: +1 (972)-362-8199; +91 895 659 5155

Email ID:[emailprotected]

Original post:
GLOBAL TESTOSTERONE REPLACEMENT THERAPY MARKET 2020 BY LATEST TECHNOLOGIES, APPLICATIONS, KEY COMPANIES, PRODUCTS, REVENUE AND GROWTH OPPORTUNITIES...

Posted in Testosterone Replacement Therapy | Comments Off on GLOBAL TESTOSTERONE REPLACEMENT THERAPY MARKET 2020 BY LATEST TECHNOLOGIES, APPLICATIONS, KEY COMPANIES, PRODUCTS, REVENUE AND GROWTH OPPORTUNITIES…

Impact of COVID-19 on Testosterone Replacement Therapy Market Analysis, Growth, Vendors, Shares, Trends, Challenges with Forecast to 2027 | Endo…

Posted: June 25, 2020 at 1:50 pm

Notice:This Content doesnt contains all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with latest update with chart and Table of Content

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Testosterone Replacement Therapy market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in future.

This Report Covers Leading Companies Associated in Worldwide Testosterone Replacement Therapy Market: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2024

The report begins with a brief introduction and market overview of the Testosterone Replacement Therapy industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed along with current trends and policies in the industry.

The key players profiled in this report include: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

Get a PDF Brochure of this Report: https://www.coherentmarketinsights.com/insight/request-pdf/2024

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Testosterone Replacement Therapy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Testosterone Replacement Therapy market

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the Testosterone Replacement Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Testosterone Replacement Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Testosterone Replacement Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Testosterone Replacement Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Get Offer on Report: https://www.coherentmarketinsights.com/insight/request-discount/2024

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

More here:
Impact of COVID-19 on Testosterone Replacement Therapy Market Analysis, Growth, Vendors, Shares, Trends, Challenges with Forecast to 2027 | Endo...

Posted in Testosterone Replacement Therapy | Comments Off on Impact of COVID-19 on Testosterone Replacement Therapy Market Analysis, Growth, Vendors, Shares, Trends, Challenges with Forecast to 2027 | Endo…

Page 980«..1020..979980981982..9901,000..»